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Abstract
Background: A major toxicity concern in radioembolization therapy of hepatic malignancies is radiation-induced
pneumonitis and sclerosis due to hepatopulmonary shunting of 90Y microspheres. Currently, 99mTc macroaggregated
albumin (99mTc-MAA) imaging is used to estimate the lung shunt fraction (LSF) prior to treatment. The aim of this study
was to evaluate the accuracy/precision of LSF estimated from 99mTc planar and SPECT/CT phantom imaging, and within
this context, to compare the corresponding LSF and lung-absorbed dose values from 99mTc-MAA patient studies.
Additionally, LSFs from pre- and post-therapy imaging were compared.
Results: A liver/lung torso phantom filled with 99mTc to achieve three lung shunt values was scanned by planar and
SPECT/CT imaging with repeat acquisitions to assess accuracy and precision. To facilitate processing of patient data, a
workflow that relies on SPECT and CT-based auto-contouring to define liver and lung volumes for the LSF calculation
was implemented. Planar imaging-based LSF estimates for 40 patients, obtained from their medical records, were
retrospectively compared with SPECT/CT imaging-based calculations with attenuation and scatter correction.
Additionally, in a subset of 20 patients, the pre-therapy estimates were compared with 90Y PET/CT-based measurements.
In the phantom study, improved accuracy in LSF estimation was achieved using SPECT/CT with attenuation and scatter
correction (within 13% of the true value) compared with planar imaging (up to 44% overestimation). The results in
patients showed a similar trend with planar imaging significantly overestimating LSF compared to SPECT/CT. There was
no correlation between lung shunt estimates and the delay between 99mTc-MAA administration and scanning, but off-
target extra hepatic uptake tended to be more likely in patients with a longer delay. The mean lung absorbed dose
predictions for the 28 patients who underwent therapy was 9.3 Gy (range 1.3–29.4) for planar imaging and 3.2 Gy (range
0.4–13.4) for SPECT/CT. For the patients with post-therapy imaging, the mean LSF from 90Y PET/CT was 1.0%, (range 0.3–
2.8). This value was not significantly different from the mean LSF estimate from 99mTc-MAA SPECT/CT (mean 1.0%, range
0.4–1.6; p = 0.968), but was significantly lower than the mean LSF estimate based on planar imaging (mean 4.1%, range
1.2–15.0; p = 0.0002).
Conclusions: The improved accuracy demonstrated by the phantom study, agreement with 90Y PET/CT in patient
studies, and the practicality of using auto-contouring for liver/lung definition suggests that 99mTc-MAA SPECT/CT with
scatter and attenuation corrections should be used for lung shunt estimation prior to radioembolization.
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Background
Transarterial radioembolization (TARE) with 90Y micro-
spheres is an established treatment for unresectable hepato-
cellular carcinoma (HCC) and for liver metastases, with
promising clinical results [1, 2]. In TARE, radioactive mi-
crospheres (glass or resin) are preferentially delivered and
permanently implanted into hepatic tumors by exploiting
the unique dual vascular anatomy of the liver. A major tox-
icity concern in TARE is radiation-induced pneumonitis
and sclerosis due to hepatopulmonary shunting of 90Y mi-
crospheres. Prior to treatment, lung shunting is evaluated
by surrogate imaging with 99mTc-macroaggregated albumin
particles (99mTc-MAA) that is assumed to mimic the distri-
bution of the microspheres. For glass microspheres, the
manufacturer’s recommendation (https://www.btg-im.com/
BTG/media/TheraSphere-Documents/PDF/TheraSphere-
Package-Insert_USA_Rev-14.pdf) for individualization of
the administered activity based on lung shunt uses an
upper limit of 30 Gy for the absorbed dose to the lung rely-
ing on limited clinical observations [3, 4].
Currently, in standard clinical practice, the lung shunt
fraction (LSF) is typically estimated by 99mTc-MAA planar
gamma camera imaging performed without accounting for
attenuation or scatter effects. Because of differences in tis-
sue densities of the lung and liver, the LSF will be overesti-
mated when attenuation correction is not performed.
Additionally, 2D imaging does not allow for accurate delin-
eation of lung and liver regions and cannot be used to esti-
mate the lung volume or mass for dosimetry. Although
99mTc-MAA SPECT/CT is performed at many centers, for
visual assessment of extra-hepatic deposition, it is not rou-
tinely used for the LSF calculation. With iterative recon-
struction, image degrading physical factors such as
attenuation and scatter can be accurately modeled in
SPECT/CT, and tomographic 3D imaging facilitates accur-
ate delineation of lung and liver volumes. There have been
past studies that report significant overestimation in planar
imaging-based LSFs compared with SPECT/CT-based esti-
mates as well as relatively good agreement in patients
undergoing Y-90 TARE [5–7]. However, these studies did
not include comparison with estimates from post-therapy
imaging. Additionally, only one of these studies [7] included
phantom measurements to access the accuracy and preci-
sion of the imaging methodology used. Because
post-therapy imaging is not part of manufacturer recom-
mendations for TARE and is not always performed, the
agreement between 99mTc-MAA-based lung shunt estimates
and post-therapy imaging-based estimates has not been well
studied. Additionally, post-therapy 90Y imaging based on ei-
ther bremsstrahlung SPECT/CT or 90Y PET/CT is challen-
ging, especially in low uptake regions such as the lung. The
use of time-of-flight information in the case of PET [8] and
model/Monte Carlo-based scatter correction in the case
SPECT [9–11] has led to improved Y-90 imaging, but these
methods are not always available with clinic systems. Apart
from the imaging methodology, another factor that can im-
pact 99mTc-MAA-based lung shunt estimation is the appar-
ent in vivo breakdown of 99mTc-MAA into smaller
aggregates and to pertechnetate over time [12, 13].
Since February 2017, at our institution, in addition to pla-
nar 99mTc-MAA imaging, SPECT/CT is performed with
two bed positions used when the entire lung and liver are
not encompassed within a single field-of-view (FOV). Thus,
imaging data was available to perform SPECT/CT-based
LSF calculation for comparison with the planar
imaging-based calculation still used in the clinic. A work-
flow that uses automatic contouring tools was implemented
to facilitate the process of SPECT/CT-based LSF estimation
in the current study and with the goal of future clinical im-
plementation. Experimental measurements with a liver/
lung torso phantom were designed to mimic typical LSF
values and imaging conditions in patients. Phantom results
that establish accuracy/precision of planar and SPECT/
CT-based LSF estimation used in our clinic are presented
together with a retrospective comparison of patient LSF
and lung absorbed dose results corresponding to the two
modalities. The impact the time delay from 99mTc-MAA in-
jection to scanning has on LSF as well as on extra hepatic
uptake in general is also evaluated. Additionally, some of
the patients were enrolled in an ongoing research study
where post-therapy 90Y PET/CT imaging was performed.
Thus, for a subset a comparison of pre-therapy vs.
post-therapy imaging-based LSF values was also performed.
Methods
Phantom study
A 99mTc phantom study was conducted to assess accur-
acy/precision of lung shunt measurements from planar
and SPECT/CT imaging. The phantom used was the
liver/lung anatomical phantom (Data Spectrum Corpor-
ation, Durham, NC, USA) consisting of a spine insert,
fillable lungs, and fillable liver modified to include two
“lesions.” The activity concentrations used to fill the
compartments are given in Table 1. Initially, the lungs
consisting of Styrofoam beads were filled with
non-radioactive water to simulate a 0% lung shunt. Next,
the lungs were filled with 99mTc mixed with water to
simulate a 6.9% lung shunt. Subsequently, the liver activ-
ity was increased (while keeping the lung activity at the
same level) to simulate a 3.6% lung shunt. This range
covers clinically realistic LSF values as evident from the
SPECT/CT patient data presented in the “Results” sec-
tion. The maximum total activity in the phantom was
195 MBq, corresponding to the 3.6% lung shunt.
Patient studies
This was a retrospective study of 40 patients who had
undergone 99mTc-MAA imaging for lung shunt assessment
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prior to radioembolization with 90Y glass microspheres
(Therasphere; BTG International Ltd., Ottawa, Canada) at
the University of Michigan Medical Center. The patient
population consisted of intrahepatic metastases from hepa-
tocellular carcinoma (16), neuroendocrine cancer (4), chol-
angiocarcinoma (4), colorectal carcinoma (6), colon cancer
(3), melanoma (3), rectal cancer (1), carcinoid (1), and ad-
renal cancer (2). The routine pre-therapy clinical protocol
consists of administration of 185–222 MBq of 99mTc-MAA
followed by planar gamma camera imaging as soon after
the procedure as possible. Additionally, either one or two
SPECT/CTs (depending on whether the patient’s liver and
entire lungs could be encapsulated in the SPECT FOV) is
performed to assess extra hepatic deposition. At our institu-
tion, reconstitution of 99mTc-MAA kits follows manufac-
turer guidelines (Jubilant DraxImage), and at the end of
synthesis, elution testing is performed daily with thin
layer chromatography to evaluate the radiochemical
purity, with an average of 97% purity for routine pro-
duction in our facility. Reconstituted kits are used
within 6 h, and radiochemical purity remains stable
prior to injection.
Twenty-eight of the 40 patients went on to receive 90Y
TARE. Twenty of these patients had post-therapy 90Y
PET/CT imaging as part of an ongoing research study,
and this data was also available. Approval by the Univer-
sity of Michigan Institutional Review Board (IRB) was
obtained to retrospectively access relevant patient data
and information. Informed consent was obtained for
post-therapy imaging performed for research purposes.
Image acquisition and reconstruction
Planar and SPECT/CT imaging for both the phantom
and patients were performed on Siemens Symbia sys-
tems (Intevo or T series) equipped with low-energy
high-resolution (LEHR) collimators. The standard clinic
acquisition protocol was used. The acquisition window
was set at 15% with an adjacent 15% low-energy scatter
window for SPECT. For SPECT, a 128 × 128 matrix, 60
views/head, non-circular continuous orbit was used. The
patient acquisition time was 70 s each for the two (chest
and abdomen) anterior/posterior planar scans and 10 s
for each SPECT projection (total scan time 10 min). The
CT for patients was performed in low-dose mode
(130 kVp; 80 mAs) during free breathing. The phantom
acquisition times were chosen to mimic count levels typ-
ical in patient imaging: 500,000 counts on the anterior
planar view and 6 million total counts for the SPECT
projections. The planar and SPECT/CT phantom acqui-
sitions at each LSF were repeated three times without
re-positioning to assess precision (repeatability).
Phantom and patient SPECT data were reconstructed
using eight iterations four subsets of OS-EM (Siemens
Flash 3D) with and without energy window-based scatter
correction (SC) and CT-based attenuation correction (AC).
Collimator-detector response modeling and an 8.4 mm
Gaussian post-filter were used in all reconstructions.
Lung shunt and dosimetry calculations
In the phantom study, for the planar imaging-based cal-
culation, the liver region of interest (ROI) was defined
on the anterior view and lung ROI on the posterior view
by a nuclear medicine technologist following the same
procedure used in patient studies. We use this approach
for ROI definition because most of the liver is closer to
the anterior body wall while using posterior view for
lung avoids attenuation in the heart. For comparison,
the phantom LSFs were also calculated using the geo-
metric mean of liver and lung counts as this approach is
used at some centers [7]. For the SPECT/CT-based cal-
culation, liver and lung volumes were defined on the
co-registered CT. LSF was calculated as:
LSF ¼ 100
 Counts in the lung
Counts in the lungþ counts in the liver
ð1Þ
For the patients, the planar LSFs were obtained from
medical records without alteration (except in one case
where the technologist had made a mistake in the calcu-
lation). These had been calculated using Eq. 1 and
counts obtained by manually segmenting the liver ROI
on the anterior view and lung ROI on the posterior view
by nuclear medicine technologists.
To determine the patient LSFs from SPECT/CT, a
semi-automatic workflow was created in MIM software
(MIM Software Inc.; Beachwood, Ohio). If two SPECT/
CT scans were necessary, the liver volume of interest
(VOI) was defined with SPECT-based thresholding on
the scan that encompassed the entire liver, and the lung
VOI was defined by CT-based thresholding on the scan
that encompassed the entire lung. If only one SPECT/
CT scan was necessary, then the liver VOI and lung VOI
were defined with the same thresholding methods, but
on the singular SPECT/CT image set. To determine the
liver VOI, the SPECT threshold level was selected based
Table 1 Injected 99mTc activity concentrations to simulate the
three different lung shunt levels
Activity concentration (kBq/mL)
0% LSF 3.6% LSF 6.9% LSF
Left lung 0 3 3
Right lung 0 3 3
Normal liver (liver minus lesions) 65 140 65
Spherical lesion 390 390 390
Ellipsoid lesion 390 390 390
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on visual agreement between the resulting contour and
the liver outline visible on the fused CT. To automate
the process, multiple liver contours corresponding to
pre-set threshold levels (0.5, 1, 2, 5, and 10% of max
counts in field-of-view) were made available in the work-
flow with the option to choose one of these contours or
define a new contour. In order to determine the lung
VOI, a Whole Body VOI was generated automatically
through a command that detects the largest contiguous
non-background region of the image by thresholding the
CT image intensities and then applying a series of mor-
phological operations. The lung VOI was automatically
generated by setting an upper Hounsfield unit (HU)
range lock of − 150 to this Whole Body VOI. This VOI
was split into a left and right section and further cleaned
using volume thresholds to remove areas in the medias-
tinum that may have been falsely included in the lung
VOI. In order to account for the motion of the liver
smearing activity into the lungs during a free breathing
SPECT scan, the most inferior 2 cm of the left and right
lung was automatically subtracted from the lung VOIs
(Fig. 1) as proposed in the past [5, 6]. Based on the
count density in the rest of the lung (the lung VOI that
excludes the most inferior 2 cm) and the total lung vol-
ume from the CT, the total lung counts were estimated
and the LSF was calculated within the workflow using
Eq. 1.
For patients that underwent the therapy, the predicted
absorbed dose to the lungs was calculated based on the
MIRD formulism [14]:
Lung dose Gyð Þ ¼ 49:38
 Total activity administered GBqð Þ
Lung mass kgð Þ
 LSF
ð2Þ
For the planar scans, the calculation was performed
assuming a standard lung mass of 1 kg. For SPECT/CT,
lung mass was determined by multiplying the CT-based
lung volume (obtained automatically within the above-
mentioned workflow) by the lung density, assumed to be
0.3 kg/l [15].
Post-therapy 90Y PET/CT imaging
Twenty of the patients were part of an ongoing research
study where they underwent 90Y PET/CT imaging
within a few hours of the TARE procedure. The 30-min
PET/CT scan performed on a Siemens Biograph mCT
with continuous bed motion was centered on the liver
and included either full or partial lung (36 cm axial
FOV). The CT was performed in a low-dose mode
(120 kVp; 80 mAs) during free breathing. The
time-of-flight PET reconstruction employed 1 iteration,
21 subsets of OSEM, and included resolution recovery
and a 5-mm Gaussian post filter. These parameters were
chosen based on a previous phantom evaluation of con-
trast, quantification, and noise [16]. The LSF based on
90Y PET/CT was also determined using the previously
mentioned workflow. When the entire lung was not
within the PET FOV (in 10/20 patients), it was necessary
to approximate the total lung counts based on the count
density in the part of the lung that was within the FOV
and the lung volume from the CT of the 99mTc-MAA
SPECT/CT.
Impact of time delay on lung shunt and extra-hepatic
uptake
To evaluate the impact of time delay on LSF and
extra-hepatic uptake, the elapsed time between
99mTc-MAA injection and imaging was obtained from
the medical records. An image review of 99mTc-MAA
planar head and neck images and thorax-upper abdom-
inal SPECT/CT of each patient was performed by a Nu-
clear Medicine Physician (KF) to evaluate extra-hepatic
uptake. Studies were rated as having none, minimal, or
definitive extra-hepatic activity.
Fig. 1 A coronal and transverse slice of a patient 99mTc-MAA SPECT/CT
processed through the workflow for auto contouring and LSF
calculation. The CT-threshold-based lung contour with and without the
2 cm exclusion region is shown as well as the SPECT threshold-based
liver contour. The lung shunt (original) refers to the value calculated
without the exclusion region
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Statistical analysis
SAS software (v9.4) was used for statistical analysis.
Paired t tests were used to compare mean LSFs between
the different imaging methods. P < 0.05 was considered
statistically significant. Correlation between estimates
from planar and SPECT/CT and between LSFs and time
delay from 99mTc-MAA injection to imaging was
assessed using Pearson’s correlation coefficient (R).
Results
Phantom study
Phantom planar and SPECT/CT images corresponding
to the three different LSFs are shown in Fig. 2. Table 2
presents the mean estimated LSFs at each true lung
shunt level along with the associated standard deviation
from the three repeat acquisitions. LSFs estimated using
the anterior liver and the posterior lung performed bet-
ter than the geometric mean method. LSFs estimated
from SPECT/CT with AC only, and AC and SC per-
formed better than estimates from SPECT/CT without
corrections and planar imaging.
Patient studies
Lung shunt from 99mTc-MAA imaging
The workflow enabled automatic determination of
SPECT/CT-based LSFs with only minimal user interven-
tion to select one of the pre-set threshold levels to best
define the liver contour (no contours were defined
manually). The selected levels (number of patients in
parenthesis) were 0.5% (2), 1% (7), 2% (20), or 5% (11).
For an example patient, the lung and liver contours used
in the LSF calculation corresponding to the different im-
aging modalities are presented in Fig. 3. The LSFs for all
patients with the different imaging modalities and with
and without 2-cm exclusion region are presented in
Table 3. With the exclusion region, there was a substan-
tial decrease in the LSF and all SPECT/CT and PET/CT
results presented in the rest of the paper are with this
correction used to mitigate motion artifacts. Results of
Table 3 show that planar imaging substantially overesti-
mates the LSF compared with SPECT/CT with AC only
and AC and SC. The mean LSF from SPECT/CT (AC
and SC) is 1.5% (range from 0.4 to 6.0%), and this value
is statistically significantly different from LSF from
planar imaging (mean 5.4%, range from 1.2 to 15.7%;
p < 0.0001). Figure 4 shows the correlation between
planar and SPECT/CT-based LSFs.
Lung absorbed dose predictions from 99mTc-MAA imaging
The average lung mass in this patient population, deter-
mined from the CT volume assuming a lung density of
0.3 kg/l, was 0.87 kg (range from 0.45 to 1.43). These
patient-specific lung mass values were used for the
SPECT/CT-based lung absorbed dose calculation while
a 1-kg mass was assumed for the planar calculation. The
lung doses corresponding to the planar and SPECT/CT
imaging-based calculations are plotted in Fig. 5 for the
twenty-eight 90Y treatments, where administered activ-
ities ranged from 0.9 to 7.9 GBq with an average value
of 3.7 GBq. Seven patients had two administrations of
Y-90, and the absorbed dose is the combined absorbed
dose from the two treatments. In all but one case (#38),
Fig. 2 Phantom images corresponding to the different true lung shunt values 0, 3.6, and 6.9% showing a anterior/posterior views for planar imaging
and b coronal and axial slices for SPECT/CT
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the absorbed dose corresponding to planar imaging was
higher than the absorbed dose corresponding to SPECT/
CT with AC and SC. The average lung absorbed dose
from planar imaging was 9.2 Gy (range from 1.3 to
29.4 Gy) and from SPECT/CT was 3.2 Gy (range from
0.4 to 13.3 Gy). There were no reported cases of sub-
acute lung toxicity; however, our follow-up time is too
short (range from 3 to 10 months) to assess late phase
toxicity.
Impact of time delay between 99mTc-MAA injection and scan
The elapsed time between 99mTc-MAA administration
and scanning was on average 74 min (range from 25
to 193). No correlation was found between the time
delay and the planar LSF (R2 = 0.04) or SPECT/CT
LSF (R2 = 0.06). Results of the image review for extra
hepatic uptake are summarized in Table 4, categorized
based on the time delay. Locations of extra hepatic
uptake observed included renal, gastric, lung, urinal,
and thyroid. An example case demonstrating defini-
tive renal and gastric uptake when imaged after a
176 min delay is shown in Fig. 6.
Lung shunt from post-therapy 90Y PET/CT
As with SPECT/CT, the workflow enabled automatic deter-
mination of PET/CT-based LSFs with only minimal user
intervention to select one of the pre-set threshold levels to
best define the liver contour. The selected levels (number
of patients in parenthesis) were 0.5% (4), 1% (3), 2% (10), or
5% (3). For the 20 patients with post-therapy imaging, the
90Y PET/CT-based LSFs with and without the exclusion re-
gion are given in Table 3. Although 7/20 patients had two
Y-90 treatment, the PET results presented here correspond
to the first treatment. Post-therapy imaging-based LSFs are
compared with pre-therapy imaging-based estimates in
Fig. 7 for all patients and show the better agreement when
SPECT/CT is used instead of planar imaging. The results
summarized in Table 5 show no statistically significant dif-
ference between the 90Y PET/CT and 99mTc-MAA SPECT/
CT-based estimates. However, there were significant mean
differences when comparing 90Y PET/CT to planar im-
aging. When compared with 90Y PET/CT, 3/20 patients
had an absolute difference in LSF that was > 5% with planar
imaging while no patients had a difference > 5% with
SPECT/CT.
Table 2 Mean lung shunt fraction (with standard deviation in
parenthesis) corresponding to planar and SPECT/CT scans of
the phantom
LSF
Actual 0.0% 3.6% 6.9%
Planar (anterior liver, posterior
lung)
1.67%
(0.01%)
5.12%
(0.03%)
8.21%
(0.05%)
Planar (geometric mean) 2.46%
(0.02%)
8.17%
(0.03%)
13.39%
(0.02%)
SPECT/CT without corrections 1.28%
(0.01%)
7.15%
(0.02%)
12.13%
(0.03%)
SPECT/CT with AC 0.67%
(0.01%)
3.98%
(0.02%)
6.83%
(0.03%)
SPECT/CT with AC and SC 0.10%
(0.07%)
3.10%
(0.01%)
6.22%
(0.03%)
b
a
c
Fig. 3 a Posterior, anterior 99mTc-MAA planar images showing manually defined liver/lung regions for LSF calculation in the clinic. A coronal b 99mTc-MAA
SPECT/CT slice and c 90Y PET/CT slice for the same patient processed through the workflow for LSF calculation
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Table 3 Patient LSFs corresponding to the different imaging modalities and with and without the 2 cm lung exclusion area
Patient LSF from
Planar (%)
LSF from SPECT/CT with 2 cm
exclusion (%)
LSF from SPECT/CT without
2 cm exclusion (%)
LSF from PET/CT with
2 cm exclusion (%)
LSF from PET/CT without
2 cm exclusion (%)
No AC or SC AC AC + SC No AC or SC AC + SC AC + SC AC + SC
1 2.5 2.0 1.4 0.6 4.7 2.4 1.1 4.5
2 15.0 3.2 2.2 1.1 6.4 3.5 2.7 15.5
3 6.3 3.1 2.1 1.8 3.5 1.9
4 10.1 7.2 5.0 4.0 11.7 7.5
5 8.4 3.9 1.6 1.2 6.1 3.1 0.5 1.0
6 12.0 5.0 2.7 1.7 6.2 3.9
7 3.7 4.7 2.9 2.3 5.0 2.4
8 3.2 2.6 1.9 1.6 6.3 4.7 0.9 2.7
9 2.9 2.4 1.7 0.8 8.4 4.7 1.3 8.8
10 2.6 1.2 0.9 0.4 3.6 2.3 0.6 4.1
11 2.8 2.3 1.4 0.8 4.1 1.6
12 2.5 2.7 1.6 0.5 5.6 2.0
13 4.6 2.2 1.4 0.8 3.9 2.1
14 3.8 1.3 1.1 0.7 2.6 1.6 0.4 1.4
15 1.4 1.1 0.9 0.5 3.3 2.0 0.9 4.4
16 9.8 1.3 1.1 0.7 2.9 2.0
17 5.9 4.2 2.7 1.8 6.3 3.3
18 9.0 7.2 4.1 2.7 13.4 7.2
19 4.3 3.6 2.5 2.2 17.9 12.6
20 3.2 1.9 1.4 1.2 2.7 1.8
21 11.0 6.0 4.0 3.4 7.1 4.0
22 4.9 3.1 2.1 1.4 3.6 1.5 0.3 0.3
23 2.1 1.4 0.3 0.7 2.1 1.3 0.4 2.2
24 2.4 1.7 1.4 0.8 5.5 4.4
25 15.7 10.6 7.5 6.0 13.8 8.7
26 2.0 3.1 2.2 1.0 6.0 2.6 1.5 3.0
27 8.0 3.5 3.2 2.5 3.8 2.5
28 2.1 2.0 1.2 0.6 3.6 1.7
29 5.9 5.6 4.1 4.1 13.1 9.1
30 2.1 2.8 1.7 0.6 7.0 2.5
31 2.8 2.4 2.1 1.6 14.1 9.6 1.0 4.7
32 13.6 5.5 3.6 2.5 7.5 4.3
33 4.2 1.3 0.9 0.4 2.0 1.0 0.5 1.0
34 6.0 3.0 2.0 1.5 7.5 5.0 0.6 3.1
35 5.8 4.2 2.8 1.6 5.8 3.2 1.5 3.7
36 2.9 2.6 1.9 0.8 5.9 3.3 1.2 2.4
37 2.8 2.4 1.6 1.0 2.4 1.1 0.4 0.4
38 1.2 1.6 1.3 0.7 3.9 3.0 0.4 8.9
39 3.5 1.3 0.9 0.4 2.7 1.3 0.6 1.9
40 4.4 3.8 2.6 1.4 8.7 5.4 2.8 4.4
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Discussion
In this study, we investigated the potential value of
99mTc-MAA SPECT/CT imaging compared with planar
imaging for lung shunt calculation prior to TARE. The
phantom study performed under clinically realistic con-
ditions demonstrated that improved accuracy in LSF es-
timation (within 13% underestimation of true value) can
be achieved using SPECT/CT with AC and SC com-
pared with planar imaging (up to 44% overestimation).
Compared with SPECT/CT with AC only, adding SC
improved the LSF estimate for the case with the lowest
LSF only. For the other cases, the underestimation in
LSF with SC is potentially due to inaccuracies in the en-
ergy window-based SC. In a previous Monte Carlo simu-
lation study [17], we demonstrated that the TEW
method overestimates scatter in the lung region, thereby
leading to an underestimation in the reconstructed
counts. Other more sophisticated model/Monte
Carlo-based methods have been shown to be superior to
energy window-based SC [10, 18, 19], but are not always
available with clinic systems. For the planar calculation,
using the anterior view only for the liver counts and
posterior view only for the lung counts, as in our patient
studies, led to higher accuracy than using the geometric
mean method. The geometric mean method results in
higher LSFs because the liver counts go down substan-
tially when the posterior view is included in the calcula-
tion while the lung counts are less sensitive to the
inclusion of the anterior view. Both planar and SPECT/
CT-based estimates had high precision except for the 0%
lung shunt case where applying AC and SC to SPECT/
CT resulted in high variability due to the very low
counts in the lung region (Table 2). Clinically, this will
have no impact because of the 0% lung shunt value. The
phantom study did not assess respiratory motion effects,
or the variability associated with manual segmentation
of the liver and lung regions in the planar scans, which
are relevant factors in clinical studies.
In patients, in addition to the overestimation in LSF due
to lower attenuation in lung tissue relative to liver tissue,
resolution effects and respiratory motion artificially in-
creases the value due to liver counts spilling over to the in-
ferior part of the lung. Hence, instead of using the entire
lung volume, an exclusion area was used with SPECT/CT
and PET/CT, but such a correction is difficult to apply in
planar imaging due to the lack of anatomical information.
In one case, the SPECT/CT-based LSF was as high as
12.6% without the exclusion region, but reduced to only
2.2% with the exclusion region. The patient results show
the same trend as in the phantom study with the SPECT/
CT-based LSF decreasing with AC and decreasing further
with SC. As in the phantom study, in general, the impact of
SC was less than the impact of AC, except at low LSFs.
However, we believe SC should be performed when avail-
able because improved accuracy was shown in the phantom
study at zero LSF and can also improve visibility/contrast
of extra-hepatic deposition. The difference between LSFs
corresponding to planar imaging and SPECT/CT was gen-
erally much higher in patients than in the phantom, which
can be attributed to the fact that the phantom was not im-
pacted by motion effects and operator variability in defining
regions both of which can significantly impact the planar
calculation in patients. The planar-based estimate can have
considerable variability associated with the manual segmen-
tation of patient liver and lung regions, which is
operator-dependent. The operator variability can be all but
eliminated with SPECT/CT-based automatic contouring
tools, such as those used in the current workflow. Addition-
ally, in patients, the planar LSFs can be affected by
extra-hepatic uptake due to breakdown of 99mTc-MAA over
Fig. 4 Correlation between planar and SPECT/CT derived lung shunt
values for all patients (N= 40). Red symbols correspond to HCC patients,
and black symbols correspond to patients with liver metastases
Fig. 5 Correlation between planar and SPECT/CT derived lung absorbed
dose values for patients who underwent therapy (N= 28). Red symbols
correspond to HCC patients and black symbols correspond to patients
with liver metastases
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time because unlike with SPECT, planar imaging does not
differentiate between activity originating in the source re-
gion and originating in overlying and underlying tissue.
There can also be scattering off of the structures that are
overlying or underlying the source region (for example,
liver counts scattering off of breast tissue that is anterior to
the lung will contribute to the planar lung counts, but not
to the SPECT VOI counts), which can be mitigated by a
simple energy window-based scatter correction. In our
study, only photopeak window data was available for the
clinic planar acquisitions; hence, scatter correction could
not be performed. The relative impact of the various effects
can be estimated by comparing the LSFs in Tables 2 and 3
with and without the different corrections and the exclu-
sion zone. Based on these results, the use of attenuation
correction and the exclusion zone had the biggest impact
on SPECT LSF. We were not able to assess the impact of
SPECT resolution recovery because all reconstructions in-
cluded this (no option to turn resolution recovery off in
Flash 3D).
Our patient and phantom results for planar vs.
SPECT/CT-based LSF estimates are consistent with the
recent report of Dittman et al. [7]. For the phantom
study, they reported 40% overestimation in LSF with pla-
nar imaging and 5% accuracy with SPECT/CT. As in
our study, for patients, they reported a much higher dif-
ference between planar and SPECT/CT-based LSF esti-
mates than in the phantom study (for patients, their
planar to SPECT/CT LSF ratio was on average 3.6, while
ours was 4.3). They reported a mean LSF of 8.3 (range
from 3.4 to 32.3%) for planar imaging and 2.9% (range
from 0.8 to 15.7%) for quantitative SPECT/CT. The cor-
responding values from our study are 5.4% (range from
1.2 to 15.7%) and 1.5% (range from 0.4 to 6.0%). Their
correlation between planar and SPECT/CT-based LSF
estimates (R2 = 0.83) was higher than the correlation we
observed (R2 = 0.46 in Fig. 4), potentially due to using a
more systematic approach for planar ROI definition in
their prospective study compared with our retrospective
use of clinically defined ROIs. Additionally, their planar
estimate was based on the geometric mean approach
while we used the anterior liver and posterior lung.
Their study did not include post-therapy LSF estimates
for comparison with ours.
The overestimation in LSF translates to an overesti-
mation in absorbed dose. In one subject, the SPECT/
CT-based absorbed dose to the lung was 6.5 Gy (lung
shunt 2.5%) while that based on planar imaging was as
high as 29.4 Gy (lung shunt 13.6%), which is close to the
recommended upper limit for treatment eligibility. The
limitation of assuming a “standard” lung mass of 1 kg
for all patients in the planar absorbed dose calculation
Table 4 Number of patients showing extra hepatic activity on
image review categorized based on the delay between the
99mTc-MAA injection and scan
Time delay (min) Number patients
in category
Number with definitive
extra hepatic activity visible
0–45 11 0
45–90 18 5
90–135 8 5
135+ 3 2
Fig. 6 99mTc-MAA SPECT/CT images corresponding to a patient where the time between injection and imaging was 176 min demonstrating
gastric mucosal and renal cortical extra-hepatic uptake
Allred et al. EJNMMI Research  (2018) 8:50 Page 9 of 12
was evident from the individual CT volume-based lung
mass for this cohort (average 0.87 kg, range from 0.45 to
1.43) used for the SPECT/CT-based calculation. The
maximum tolerable dose to the lung from Y-90 micro-
spheres is not well established. Historically, significant
toxicity was associated with a total lung dose of 25 Gy in
external beam radiation therapy [20], but this is likely
not applicable to TARE due to the non-uniform dose
distribution of microspheres. The 30 Gy upper limit rec-
ommendation of the manufacturer is based on radiation
pneumonitis in two clinical reports where lung absorbed
dose was calculated from 99mTc-MAA planar imagi-
ng-based LSFs [3, 4]. The relatively poor correlation ob-
served in the present study between planar and SPECT/
CT-based LSFs and absorbed doses (Figs. 4 and 5) makes
it difficult to translate these past planar imaging-based
findings to SPECT/CT-based limits. Obtaining accurate
LSFs and lung tolerability dose estimates from SPECT/
CT-based calculation could allow individual adjusted
doses that improve therapeutic outcome while minimizing
pulmonary fibrosis.
There was no statistically significant difference be-
tween mean LSF estimates from 90Y imaging and
estimates based on pre-therapy 99mTc-MAA SPECT/CT
with AC and SC. As evident in Fig. 7, the absolute differ-
ence between Y-90 PET and 99mTc-MAA SPECT/
CT-based estimates are small and will not be clinically
important at these low LSFs (the largest difference is for
patient 2, where the two LSFs are 2.6 and 1.1%, which
translates to lung absorbed doses of 3.6 and 1.5 Gy, re-
spectively). For planar imaging, the differences are larger
(the largest difference is for patient 2, where the two
LSFs are 2.6 and 12.3%, which translates to lung
absorbed doses of 3.6 and 15.6 Gy, respectively). The ob-
servations of the current study need to be tested with a
larger patient cohort including patients with higher
LSFs, which can be difficult because high lung shunting
is not typical, and the rare cases may be excluded from
treatment. A past study with 14 patients reported that
99mTc-MAA SPECT/CT imaging does not accurately
predict lung absorbed doses after 166-Ho TARE [21]. A
potential explanation for the disparity was the difference
in 99mTc-MAA and Ho-166 microsphere distributions
due to differences in stability and size of the MAA parti-
cles and the microspheres, which is also a concern with
Y-90 microspheres.
Fig. 7 Comparison of pre-therapy 99mTc-MAA and post-therapy 90Y PET/CT-based lung shunt estimates (N = 20)
Table 5 Comparison of Y-90 PET/CT vs. 99mTc-MAA imaging-based LSFs for the 20 patients that had post-therapy imaging
LSF, mean (range) P* Maximum absolute
difference in LSF (%)
99mTc-MAA planar imaging 4.1% (1.2–15.0) 0.0002 12.3
99mTc-MAA SPECT/CT (AC and SC) 1.0% (0.4–1.6) 0.968 1.6
90Y PET/CT 1.0% (0.3–2.8)
*P value for significance of difference between mean LSF from indicated method and Y-90 PET/CT
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There was no correlation between 99mTc-MAA-based
LSFs and the time delay between injection and scanning.
However, in the current study, most of the patients (29/
40) were scanned within 90 min of 99mTc-MAA admin-
istration (Table 4). A study of four patients who under-
went repeat planar whole-body imaging up to 5 h after
99mTc-MAA administration reported marked increase in
lung shunt with time (mean lung shunt was 9.3, 14.7,
and 22.1% for time intervals of < 1, 1–4, and > 4 h) [13].
In visual assessment of our patient cohort, extra hepatic
uptake tended to be more likely in patients with a longer
delay between MAA administration and scanning
(Table 4). This can be attributed to the breakdown of
99mTc-MAA over time followed by localization of prod-
ucts in the gastric and renal cortex, which warrant early
imaging to improve image quality by minimizing this
background activity.
A limitation of the phantom study was that it did not
include respiratory motion, which prevented evaluation
of the effect of breathing and validation of the use of the
lung exclusion region. Motor controlled movable nuclear
medicine phantoms have been designed to investigate
motion effects [22] and can be considered in a future
study. Other limitations of the study include the hetero-
geneous patient population and the small sample size,
especially for post-therapy imaging, where only 20 stud-
ies were available as this was not part of the routine clin-
ical procedure.
Conclusions
A phantom study with clinically realistic uptake patterns
for the liver and lung demonstrated the improved accur-
acy of lung shunt estimates based on SPECT/CT with
attenuation and scatter corrections over estimates from
planar imaging. The patient studies demonstrated the
same trend observed in the phantom study with sub-
stantially higher lung shunt estimates from planar im-
aging compared with those determined by SPECT/CT
with corrections. There was no statistically significant
difference between LSFs from post-therapy 90Y PET/CT
and pre-therapy 99mTc-MAA SPECT/CT with attenu-
ation and scatter corrections. There was no correlation
between lung shunt estimates and the time delay be-
tween MAA injection and scanning, although on visual
assessment, there was evidence of increased off-target
uptake in extra-hepatic organs with time. In summary,
the improved accuracy demonstrated by the phantom
study, the agreement with 90Y PET/CT and practicality
of using auto-contouring for liver/lung definition sug-
gests that 99mTc-MAA SPECT/CT should be used for
lung shunt estimation in TARE.
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